Clinical Trial

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-13; most recent amendment 2025-03-28.
Trial Details
NCT Number NCT05731050
Lead Sponsor NovelMed Therapeutics
Conditions PNH - Paroxysmal Nocturnal Hemoglobinuria
Enrollment 6 participants
Start Date 2026-06
Primary Completion 2027-09 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-03-30